Primary Biliary Cholangitis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

• In 2022, there will be more than 500,000 diagnosed prevalent cases of PBC across 16 pharmaceutical markets.
• There are three leading marketed products for the treatment of PBC, Intercept Pharmaceuticals is a key player in the disease space.
• The PBC pipeline consists of 30 pharmaceutical therapies spanning all stages of development, with approximately 90% of drugs in mid-to-early-stage development.
• Intercept Pharmaceuticals dominate clinical trial development in PBC, with the US emerging as the key country for conducting trials in PBC.
• Deals involving acquisitions were the most common type of deals in the US relating to companies involved in developing PBC assets.
• Therapeutic options for PBC patients continue to be limited, with only one new therapy expected to reach the market during the next 18 months.

Scope

Components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Retail or Manufacturer Price of Products
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Primary Biliary Cholangitis market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Primary Biliary Cholangitis market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.